Related Experiment Videos
Matrix metalloproteinase inhibitors: current developments and future perspectives
R Hoekstra1, F A Eskens, J Verweij
1Department of Medical Oncology, Rotterdam Cancer Institute, Daniel den Hoed Kliniek and University Hospital, Rotterdam, The Netherlands. hoekstra@oncd.azr.nl
The Oncologist
|October 25, 2001
Summary
Matrix metalloproteinases (MMPs) degrade the extracellular matrix, aiding tumor invasion and metastasis. Matrix metalloproteinase inhibitors (MMPIs) are being developed to target this process, with early clinical studies showing promise for cancer treatment.
Area of Science:
- Oncology
- Biochemistry
- Molecular Biology
Background:
- Malignant tumors exhibit invasive growth and metastasis, processes facilitated by the enzymatic degradation of the extracellular matrix (ECM).
- Elevated concentrations of matrix metalloproteinases (MMPs), enzymes crucial for ECM breakdown, are frequently observed in human tumors.
- The role of MMPs in cancer progression is a significant area of research.
Purpose of the Study:
- To review the fundamental mechanisms of ECM degradation.
- To emphasize the specific role of MMPs in cancer progression.
- To present an overview of preclinical and clinical studies involving matrix metalloproteinase inhibitors (MMPIs) and discuss their future therapeutic potential.
Main Methods:
- Review of existing literature on ECM degradation and MMPs.
- Analysis of preclinical data from studies on MMPIs.
- Evaluation of early clinical trial results for MMPIs.
Main Results:
- MMPs are key enzymes involved in ECM degradation, promoting tumor invasion and metastasis.
- Numerous MMPIs have been developed, with several undergoing clinical evaluation.
- Initial clinical studies with MMPIs have yielded preliminary results that warrant further investigation.
Conclusions:
- Targeting MMPs with MMPIs represents a potential therapeutic strategy for cancer.
- Further research and clinical trials are necessary to establish the efficacy and safety of MMPIs.
- The future perspective for MMPIs in cancer treatment is cautiously optimistic, pending further data.